Is Invesco Stock Outperforming the Dow?

Atlanta, Georgia-based Invesco Ltd. (IVZ) is a publicly owned investment management firm that provides its services to retail clients, institutional clients, high-net-worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds. The company has a market cap of $13.7 billion and manages separate client-focused equity and fixed-income portfolios, and more. 

Companies with a market cap of $10 billion or more are typically referred to as “large-cap stocks.” IVZ fits squarely into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the asset management industry. The company operates in more than 20 countries and manages around $2.2 trillion in assets internationally. 

Despite its strength, IVZ is down 8.1% from its 52-week high of $33.66, touched on Aug. 28. Moreover, IVZ has surged 19.5% over the past three months and has outpaced the Dow Jones Industrial Average ($DOWI), which has declined marginally during the same period.      

Zooming out a little further, the scenario remains the same. Over the past 52 weeks, the stock has grown 38.3%, outpacing DOWI’s 12.8% gain.        

IVZ has been trading above its 200-day moving average since April, indicating long-term bullish momentum, and below its 50-day moving average since this month. 

On July 28, IVZ reported its Q2 2026 earnings, delivering impressive revenue growth. Its Assets Under Management (AUM) for the quarter rose 23.4%, pushing its revenue to rise by an impressive 65.3% year-over-year to $1.3 billion and surpassing the Street’s estimates. Moreover, its adjusted EPS amounted to $0.71, also topping the consensus estimates, along with a rise in its adjusted operating margin to 37.5%, driven by robust growth in ETFs and Index, QQQ, China JV, and Private Markets.  

When stacked against its peer, Ares Management Corporation (ARES), IVZ has outperformed as well. Over the past year, ARES stock has declined 25.3%.       

Sentiment on IVZ remains moderately optimistic. Among the 15 analysts covering the stock, the consensus rating is a “Moderate Buy.” Its mean price target of $34.16 suggests 12% upside from current levels. 

On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.